Source comparison
SS-31 Dosage Cardioprotection 2026: Model-Specific Comparison
Ischemia-Reperfusion Injury 0.25–1.0 mg/kg IV bolus or short infusion Single dose or 4-hour infusion Infarct size reduction of 30–40% at 0.5 mg/kg with no further benefit at higher doses Optimal dose is 0.5 mg/kg. Escalation wastes compound without improving o
This comparison does not assign a generated winner or score.
- Ischemia-Reperfusion Injury
- 0.25–1.0 mg/kg
- IV bolus or short infusion
- Single dose or 4-hour infusion
- Infarct size reduction of 30–40% at 0.5 mg/kg with no further benefit at higher doses
- Optimal dose is 0.5 mg/kg. Escalation wastes compound without improving outcomes
- Chronic Heart Failure (HFpEF)
- 1.0–4.0 mg/kg
- Subcutaneous daily
- 28–90 days
- Functional improvement at 4.0 mg/kg not seen at 1.0 mg/kg
- Sustained dosing at upper range required for chronic mitochondrial restoration
- Mitochondrial Myopathy (Barth Syndrome)
- 3.0–5.0 mg/kg
- 12+ weeks
- Significant ejection fraction improvement at 5.0 mg/kg in severe cardiolipin deficiency
- High doses justified only in genetic mitochondrial disorders. Not applicable to acquired injury
- Doxorubicin Cardiotoxicity Prevention
- 0.5–2.5 mg/kg
- IV or subcutaneous
- Concurrent with chemotherapy cycles
- Reduced oxidative damage and preserved ejection fraction at 2.5 mg/kg
- Mid-range dosing effective because mitochondrial injury accumulates over repeated chemotherapy exposures
- The practical takeaway: acute cardioprotection research achieves ceiling effects at 0.5–1.0 mg/kg, chronic applications require 2.0–4.0 mg/kg sustained dosing, and only severe genetic mitochondrial dysfunction justifies doses above 4.0 mg/kg. Researchers designing protocols outside these ranges should revisit their mechanistic assumptions. Either the dose is insufficient to saturate mitochondrial binding sites, or it's wastefully exceeding saturation without enhancing the measurable outcome.